APA (7th ed.) Citation

JY, S., T, H., JL, Z., JH, L., ML, W., J, Y., . . . J, W. (2024). Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation. American journal of cancer research, 14(2), 407.

Chicago Style (17th ed.) Citation

JY, Su, Huang T, Zhang JL, Lu JH, Wang ML, Yan J, Lin RB, Lin SY, and Wang J. "Leveraging Molecular Targeted Drugs and Immune Checkpoint Inhibitors Treat Advanced Thyroid Carcinoma to Achieve Thyroid Carcinoma Redifferentiation." American Journal of Cancer Research 14, no. 2 (2024): 407.

MLA (9th ed.) Citation

JY, Su, et al. "Leveraging Molecular Targeted Drugs and Immune Checkpoint Inhibitors Treat Advanced Thyroid Carcinoma to Achieve Thyroid Carcinoma Redifferentiation." American Journal of Cancer Research, vol. 14, no. 2, 2024, p. 407.